Evidence map›Paper›PMID 37636517›Full record

ArticleOpen forum infectious diseases2023

Viral Determinants of Acute COVID-19 Symptoms in a Nonhospitalized Adult Population in the Pre-Omicron Era.

Sarah A Goldberg, Scott Lu, Miguel Garcia-Knight, Michelle C Davidson, Michel Tassetto, Khamal Anglin, Jesus Pineda-Ramirez, Jessica Y Chen, Paulina R Rugart, Sujata Mathur and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Sarah A GoldbergDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-8642-1468
Scott LuDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Miguel Garcia-KnightDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA.
Michelle C DavidsonSchool of Medicine, University of California, San Francisco, San Francisco, California, USA.
Michel TassettoDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA.
Khamal AnglinInstitute for Global Health Sciences, University of California, San Francisco, San Francisco, California, USA.
Jesus Pineda-RamirezInstitute for Global Health Sciences, University of California, San Francisco, San Francisco, California, USA.
Jessica Y ChenInstitute for Global Health Sciences, University of California, San Francisco, San Francisco, California, USA.
Paulina R RugartDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Sujata MathurDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Carrie A FormanCollege of Medicine, Drexel University, Philadelphia, Pennsylvania, USA.
Kevin C DonohueSchool of Medicine, University of California, San Francisco, San Francisco, California, USA.
Glen R AbediCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Sharon SaydahCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Melissa Briggs-HagenCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Claire M MidgleyCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Raul AndinoDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA.
Michael J PelusoDivision of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-0585-6230
David V GliddenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
J Daniel KellyDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco · USCenters for Disease Control and Prevention · USDrexel University · USSan Francisco General Hospital · USSan Francisco VA Medical Center · US

Funding

Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
Understanding the epidemiology and natural history of unrecognized Ebola virus infectionK23AI146268 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KELLY, JOHN DANIEL · 2019 to 2022
$748k
NIAID NIH HHS K23 AI146268NIAID NIH HHS K23 AI157875NIAID NIH HHS L30 AI126521NIAID NIH HHS L30 AI147159NIAID NIH HHS T32 AI060530
6 · The paper itself

Abstract

Background: The influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA level and presence of infectious virus on symptom occurrence is poorly understood, particularly among nonhospitalized individuals. Methods: The study included 85 nonhospitalized, symptomatic adults, who were enrolled from September 2020 to November 2021. Data from a longitudinal cohort studied over 28 days was used to analyze the association of individual symptoms with SARS-CoV-2 viral RNA load, or the presence or level of infectious (culturable) virus. Presence of infectious virus and viral RNA load were assessed daily, depending on specimen availability, and amount of infectious virus was assessed on the day of maximum RNA load. Participants were surveyed for the start and end dates of 31 symptoms at enrollment and at days 9, 14, 21, and 28; daily symptom presence was determined analytically. We describe symptoms and investigate their possible association with viral determinants through a series of single or pooled (multiple days across acute period) cross-sectional analyses. Results: There was an association between viral RNA load and the same-day presence of many individual symptoms. Additionally, individuals with infectious virus were more than three times as likely to have a concurrent fever than individuals without infectious virus, and more than two times as likely to have concurrent myalgia, chills, headache, or sore throat. Conclusions: We found evidence to support the association of viral RNA load and infectious virus on some, but not all symptoms. Fever was most strongly associated with the presence of infectious virus; this may support the potential for symptom-based isolation guidance for COVID-19.

Identifiers

PMID37636517
PMCPMC10456204
OpenAlexW4386188377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.